Abstract: The invention relates to active particles, including core-shell particles, having low burst, controllable, sustained release which are useful for coating seeds. The active particles can also be used in sprayable and dry formulations for treating soil or plants. The particulate coating can also contain inert organic or inorganic material. The invention also relates to methods for preparing the active particles. The methods include: adding additional material to core particles to form a shell, removing active ingredient from a core surface to create an active-depleted shell, and crosslinking the outer layers of a core to form a shell.

Abstract: PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery.

Abstract: Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric.

Abstract: The invention relates to active particles, including core-shell particles, having low burst, controllable, sustained release which are useful for coating seeds. The active particles can also be used in sprayable and dry formulations for treating soil or plants. The particulate coating can also contain inert organic or inorganic material. The invention also relates to methods for preparing the active particles. The methods include: adding additional material to core particles to form a shell, removing active ingredient from a core surface to create an active-depleted shell, and crosslinking the outer layers of a core to form a shell.

Abstract: An embodiment of the present invention provides a display system, and the display system comprises a light beam emitting device, emitting a first light beam for marking an input position and a second light beam for confirming the input position, the first light beam being visible light, and the second light beam differing from the first light beam; and a display device, comprising a displaying area, photo-sensitive devices distributed within the displaying area, processing devices coupled with the photo-sensitive devices. The photo-sensitive devices are used for sensing the second light beam projected upon the displaying area and achieving a sensing result; the processing devices are used for determining the projecting position of the second light beam upon the displaying area according to the sensing result, and performing a corresponding operation based on the sensing result. The present invention is capable of performing remote touch operation on the display device.

Abstract: Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations.

Abstract: An exemplary display system (2) includes a display device (23), an image sensor (20), and a microprocessor unit (21). The image sensor includes an image sensor unit (24) and a digital signal processor unit (22) integrated therein. The image sensor unit is configured for generating a current. The digital signal processor includes a size regulator (221) configured for receiving the current, generating an analog image signal according to the current, and providing the analog image signal to the display device. The microprocessor unit is configured for initializing the image sensor unit.

Abstract: PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery.

Abstract: Compositions for the controlled delivery of active ingredients, for example, drugs, cosmetic materials, and agricultural materials. The compositions include a multiplicity of particles, each of the particles comprising (1) a microstructure comprising a semicrystalline polymer which has a peak melting temperature, Tp, of at least 20° C., and (2) the active ingredient. The microstructure comprises (i) crystalline domains of the semicrystalline polymer, the crystalline domains being separate from each other, and (ii) amorphous domains of the semicrystalline polymer, the amorphous domains providing a multiplicity of tortuous paths between the crystalline domains. At least part of the active ingredient is present in the amorphous domains. One of many valuable uses for the compositions is to provide a coating on a seed, for example a coating containing one or more of an insecticide, a fungicide, a nutrient, a biotic, a growth regulator and an herbicide.

Abstract: Compositions for delivering release materials, for example drugs, agricultural materials, other bioactive materials, cosmetic materials, organic or inorganic compounds which take part in or catalyse a chemical reaction, a fragrance-emitting material for a vaporizer, or a lubricating material. The release material is associated with a crystalline carrier. The carrier may be a crystalline polymer containing a plurality of crystalline groups or a crystalline monomer which contains a single crystalline group, the crystalline group preferably comprising a straight chain polymethylene radical containing at least 16 carbon atoms. Some of the carriers are obtained by modifying hyaluronic acid, collagen, gelatin, a polysaccharide, a carbohydrate or cyclodextran. The release material may contain a similar crystalline group, for example may be an active compound which has been modified to introduce a crystalline group.

Abstract: Delivery of drugs in association with PLGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units.

Abstract: An exemplary liquid crystal module (20) includes liquid crystal panel (200) and a driving chip (210). The driving chip includes an interface circuit (230), a storing member (260), and a plurality of input ports. The plurality of input ports are configured for receiving display data. The storing member and the interface circuit share at least one common input port of the plurality of input ports. The storing member receives at least one mode selection signal for controlling a working mode of the driving chip via the at least one common input port in a first period of time. The storing member outputs the at least one mode selection signal to the interface circuit, and then the interface circuit receives the display data via the plurality of input ports including the at least one common input port according to the working mode in a second period of time.

Abstract: Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric.

Abstract: Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations.

Abstract: Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric.

Abstract: Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations.

Abstract: Systems and methods for delivering personal care materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the cosmetic materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric.

Abstract: Delivery of drugs in association with PLGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units.

Abstract: An exemplary liquid crystal module (20) includes liquid crystal panel (200) and a driving chip (210). The driving chip includes an interface circuit (230), a storing member (260), and a plurality of input ports. The plurality of input ports are configured for receiving display data. The storing member and the interface circuit share at least one common input port of the plurality of input ports. The storing member receives at least one mode selection signal for controlling a working mode of the driving chip via the at least one common input port in a first period of time. The storing member outputs the at least one mode selection signal to the interface circuit, and then the interface circuit receives the display data via the plurality of input ports including the at least one common input port according to the working mode in a second period of time.

Abstract: The invention discloses a novel package structure of integrate circuit or discrete device and packaging method, and includes the lead pins adjacent to the island; another metal layer formed at the bottom of the island; another metal layer formed at the bottom of lead pins; chip mounted on the island; wires bonded between the chip and the lead pins; the molded body encapsulating the top surface and side surface of the island and the lead pins, small protrusions of the island and the lead pins below the molded body; in the individual package, the number of the island can be one or more, lead pins can be arrayed at one side of the island, also can be arrayed at two sides or three sides of the island, one or two rows of lead pins can be located around the island. The invention provides strong welding, good quality, low cost, smooth production, wide applicability, flexible arrangement of the chips.